Journal of Clinical Endocrinology & Metabolism, Vol 59, 453-462, Copyright © 1984 by Endocrine Society

ARTICLES

Preferential measurement of insulin-like growth factor (IGF) I-related peptides in serum with the aid of IGF-binding proteins (IGF BPs) produced by rat liver in culture. Estimation of serum IGF BP levels

M Binoux, D Seurin, C Lassarre and M Gourmelen

A protein-binding assay for insulin-like growth factor (IGF) was developed which preferentially measures IGF I-related peptides in serum. Binding proteins (BPs) extracted from the culture media of livers from approximately 4-week-old rats were used in the assay, with pure IGF I as tracer and a partially purified IGF preparation as standard. Serum samples were gel filtered in acetic acid to separate the IGFs from their BPs. IGFs could be detected with this assay in extracts corresponding to as little as 0.2 microliter normal serum. The affinity of these liver BPs was greatest for IGF I. IGF II, somatomedin A, and multiplication-stimulating activity were found to be 2, 3, and 10 times less potent, respectively, than IGF I in displacing [125I]IGF I. There was no cross-reaction with insulin and proinsulin, structurally the most closely related peptides. There was a highly significant correlation (r = 0.98, P less than 0.001) between IGF values obtained from simultaneous assays, using either 1) somatomedin C/IGF I antibodies, or 2) the liver BPs, for acromegalic, normal, and hypopituitary serum extracts. Nevertheless, the protein-binding assay yielded values 1.7-fold those of the RIA. The BPs therefore do not possess the specificity of the antibodies for IGF I, but they do have the advantage of being less species specific in that they permit measurement of IGFs in the rat (among others) with the same sensitivity as in man. The validity of the assay was demonstrated both by the studies of IGF levels as a function of age, which yielded a profile characteristic of IGF I, and by the GH-dependence of the IGF levels measured. Mean IGF levels (+/- SEM) were the following: 1.03 +/- 0.03 U/ml in normal adults; 2.62 +/- 0.10 in acromegalic patients; 0.19 +/- 0.01 in patients with total GH deficiency; 0.58 +/- 0.04 in patients with partial GH deficiency (the reference serum being assigned a potency of 1 U IGF/ml). Human GH administration (6 mg/m2, im) to untreated hypopituitary patients on average provoked a 2-fold increase in IGF levels within 24 h. In hypophysectomized rats there was a close relation between the IGF level attained and the dose of GH administered (P less than 0.001). IGF BPs were titrated by incubating different concentrations of the serum extracts with [125I]IGF I and comparing these with a BP preparation obtained from the reference serum used in the IGF assay and arbitrarily assigned a value of 1 U IGF BP/ml.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				B. Ducos, S. Cabrol, M. Houang, L. Perin, M. Holzenberger, and Y. Le Bouc IGF Type 1 Receptor Ligand Binding Characteristics Are Altered in a Subgroup of Children with Intrauterine Growth Retardation J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5516 - 5524. [Abstract] [Full Text] [PDF]

				M. Holzenberger, G. Hamard, R. Zaoui, P. Leneuve, B. Ducos, C. Beccavin, L. Perin, and Y. Le Bouc Experimental IGF-I Receptor Deficiency Generates a Sexually Dimorphic Pattern of Organ-Specific Growth Deficits in Mice, Affecting Fat Tissue in Particular Endocrinology, October 1, 2001; 142(10): 4469 - 4478. [Abstract] [Full Text] [PDF]

				N. Boulle, C. Gicquel, A. Logie, R. Christol, J.-J. Feige, and Y. Le Bouc Fibroblast Growth Factor-2 Inhibits the Maturation of Pro-Insulin-Like Growth Factor-II (Pro-IGF-II) and the Expression of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in the Human Adrenocortical Tumor Cell Line NCI-H295R Endocrinology, September 1, 2000; 141(9): 3127 - 3136. [Abstract] [Full Text] [PDF]

				M. Holzenberger, P. Leneuve, G. Hamard, B. Ducos, L. Perin, M. Binoux, and Y. Le Bouc A Targeted Partial Invalidation of the Insulin-Like Growth Factor I Receptor Gene in Mice Causes a Postnatal Growth Deficit Endocrinology, July 1, 2000; 141(7): 2557 - 2566. [Abstract] [Full Text] [PDF]

				E. Gay, D. Seurin, S. Babajko, S. Doublier, M. Cazillis, and M. Binoux Liver-Specific Expression of Human Insulin-Like Growth Factor Binding Protein-1 in Transgenic Mice: Repercussions on Reproduction, Ante- and Perinatal Mortality and Postnatal Growth Endocrinology, July 1, 1997; 138(7): 2937 - 2947. [Abstract] [Full Text] [PDF]

				B. C. Villafuerte, W. Zhao, A. C. Herington, R. Saffery, and L. S. Phillips Identification of an Insulin-responsive Element in the Rat Insulin-like Growth Factor-binding Protein-3 Gene J. Biol. Chem., February 21, 1997; 272(8): 5024 - 5030. [Abstract] [Full Text] [PDF]

				M. Menouny, M. Binoux, and S. Babajko Role of Insulin-Like Growth Factor Binding Protein-2 and Its Limited Proteolysis in Neuroblastoma Cell Proliferation: Modulation by Transforming Growth Factor-{beta} and Retinoic Acid Endocrinology, February 1, 1997; 138(2): 683 - 690. [Abstract] [Full Text] [PDF]